A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Completed

Plain-English translation of NCT02443324 on ClinicalTrials.gov ↗ · Source last updated July 2024 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(22 sites)

United States

Yale University School of Medicine, New Haven, Connecticut

Florida Cancer Specialists, Fort Myers, Florida

Florida Cancer Specialists and Research Institute, St. Petersburg, Florida

Tennessee Oncology PLLC, Chattanooga, Tennessee

Sarah Cannon Research Institute SCRI, Nashville, Tennessee